Sift Healthcare

RevProtect's central function is predicting how a payer will respond to a claim and turning that prediction into an operational action. Models connect clinical documentation with claims and remittance history, identify cases at risk and estimate the recovery potential of denied accounts. Similar case comparisons and payment outcome feedback support the recommendations.

Reporting, data normalization and worklists are useful supporting functions, but they do not replace the learned assessment of payer behavior. The current offer therefore depends on AI for its principal value, with prevention and recovery built around model outputs rather than a conventional dashboard alone.

Recommendations are directed to specific teams, with utilization review staff able to escalate a case to a physician advisor. The architecture includes confidence thresholds and escalation rules, and presents actions with a rationale rather than only a risk score. These are concrete elements of oversight. The actual threshold values, circumstances requiring a stop and procedures for rejecting or reversing an action are not specified.

Prevention pages also acknowledge that denials and downgrades still occur, so reduced risk is not presented as universal error free output. The available workflow supports supervised intervention without describing every control needed for unattended execution.

The approach combines reimbursement prediction, comparisons with similar paid and denied cases, nearest neighbor analysis and role based playbooks. Inputs include clinical documentation, 837 claims and 835 remittances, with later outcomes used to refine payer specific patterns. This identifies meaningful analytical methods and the kinds of information they use. Model families, parameter versions, training cohort boundaries and update schedules are not supplied.

Plain language recommendations are described without a named language model or a clear account of how generated text is checked against the analytical result. The architecture is more explicit than the underlying model implementation.

Sift explains the analytical layers behind RevProtect, including similarity modeling, nearest neighbor comparisons and playbooks derived from reimbursement patterns. It does not enumerate the organizations that host or process those models, or identify a supplier for any language generation component. The website policy names marketing tools, but explicitly excludes product data, so those names are not a product subprocessor list.

Training and retention terms for outside model services are also unspecified. The account provides an architecture, while leaving the processing chain for clinical inputs and generated recommendations unresolved at the level of named parties.

A May 2026 account describes RevProtect scoring 4,245 aged denied accounts with $43 million in open balances. After five months, the health system recovered $13 million, with 98% of overturned dollars attributed to the highest scoring half of accounts. The method and cohort are more specific than a generic savings claim, but the customer is unnamed and the account lacks an independent comparison.

A separate Hartford HealthCare partnership is named and dated, with validation framed as planned work. Earlier patient collection experiments concern a different product application and do not establish performance for current denial prevention recommendations.

RevProtect continually incorporates payment outcomes and successful interventions into its predictive process. This explains how its performance can adapt as payer behavior changes, but not how patient information is retained, deidentified or reused across customers. The current website policy excludes product processing, and its retention provisions concern contact and marketing data.

Numerical retention limits for clinical inputs, derived features, recommendations and backups are not stated for RevProtect. Neither are model training permissions or deletion procedures for those materials. Confidence controls around a recommendation address decision quality, while the PHI lifecycle remains an independent and unresolved part of the public product description.

The April 2026 privacy policy explicitly applies only to the public website and excludes data processed within Sift's products. It therefore does not establish the terms for clinical records, claims or remittances used by RevProtect. Current product pages do not supply business associate agreement availability, public agreement terms or a service specific account of PHI obligations.

An older Rev/Track announcement describes a HIPAA compliant database, but that statement concerns an earlier named product. It does not settle the current offer's contractual posture. Product processing and subcontractor responsibilities remain separate from the website's marketing and analytics practices.

The current RevProtect material does not identify a SOC 2 report, ISO certificate, HITRUST assessment or another independent security artifact. Its website privacy policy concerns marketing visitors and does not describe the product's security assessment boundary. Historical HIPAA language for Rev/Track is a compliance assertion for an earlier offer, not evidence of a current outside security audit. No public trust center or assessment scope accompanies the current product pages.

This leaves the status of independent assurance unresolved; it does not establish that security controls are absent. The relevant scope would include clinical data ingestion, prediction processing and delivery into customer workflows.

RevProtect is primarily positioned around reimbursement, documentation and payer behavior, but its recommendation scope includes tests, laboratory work and assessments needed to establish medical necessity. That language reaches beyond identifying a missing billing field and can influence clinical work. No current FDA status or explicit regulatory explanation is attached to that scope.

Escalation to a physician advisor and role specific guidance provide review context, but they do not by themselves resolve the intended use boundary. The public description leaves unclear whether the product only identifies absent existing evidence or also recommends new diagnostic work for an individual patient.

The validation layer tracks adverse payment outcomes, appeal results, documentation interventions and changes in payer behavior. Feedback informs later scoring, and confidence rules are intended to constrain recommendations. This is a described monitoring process, rather than a claim that models remain static after deployment. However, model release approval, rollback criteria and independent governance assessment are not specified.

There are also no subgroup fairness methods or results for patient demographics, provider populations or payer related disparities. Monitoring financial success can reveal operational drift without establishing that a recommendation is clinically appropriate or equitable for every affected population.

Recommendations include supporting rationale, and performance reporting connects interventions with eventual payment outcomes. These features let staff inspect a result and revisit an unsuccessful approach. An optional performance linked engagement ties commercial success to reduced adverse payment outcomes, but its public terms do not define a guaranteed result, a fee at risk or a remedy for an incorrect recommendation.

It is therefore unclear what financial obligation would arise when an output is wrong. Claims about recovered dollars describe observed cases rather than a warranty. Traceability and commercial alignment are present without a specified correction right or indemnity for the affected customer.

RevProtect aggregates clinical information with 837 claim and 835 remittance data. Results can appear in Sift's own interface, through an API or in existing EHR and third party worklists. That establishes the intended data flow and workflow integration pattern. The current offer does not name a verified EHR connector with a documented production read and write path.

References to Epic in general integration guidance and older patient payment listings do not establish the scope of a current RevProtect connection. Supported transactions, reconciliation behavior and responsibility for integration failures remain unspecified at the product level.

Customers can use Sift's interface, embed recommendations in existing tools or deploy through a strategic partner. These choices describe how users receive the intelligence, rather than where the underlying processing runs. The public product account does not identify a hosting provider, processing region, tenant isolation method or a customer hosted alternative. The website privacy policy cannot fill those gaps because it expressly excludes product data.

A browser accessible interface implies a hosted service, but does not establish residency for clinical records, model features or backups. Partner delivery also leaves the division of operational responsibility unclear.

RevProtect is available through an engagement tied to measured reductions in denials and other adverse payment outcomes. This makes the intended commercial relationship more specific than a generic sales demonstration: the engagement is designed around financial results rather than activity, licenses or usage. However, no fee percentage, outcome calculation formula, minimum charge or example invoice is given.

The amount attributable to the product, baseline period and handling of changing payer behavior remain contract matters. Illustrative revenue protection opportunities describe potential benefit, not the customer's bill. Implementation and integration charges are also unspecified.

The current focus is hospitals and health systems, with recommendations tailored to clinical documentation improvement, utilization review, coding and patient financial services. Risk is analyzed by payer, diagnosis related group, service line and time period. The product examples include inpatient documentation and level of care decisions, while an operational account addresses outpatient rehabilitation and oncology authorization patterns.

Hartford HealthCare is a named collaboration, but the announcement describes validation to be undertaken. The detailed recovery case leaves the health system unnamed. These sources establish a broad intended hospital workflow without comparable validation across specialties or care settings.